Figure 5.

Effects of Vgf-shRNA and/or GLYX-13 (10mg/kg, i.p.) on the level of pAKT, AKT, pmTOR, mTOR, peEF2, and VGF in hippocampus of mice. (a) Representative immunoblots of pAKT, AKT, pmTOR, mTOR, peEF2, and VGF detected by Western blotting with tissues from the hippocampus; the rest of the panels are quantification of the immunoblotting bands of pAKT (b), AKT (c), pmTOR (d), mTOR (e), peEF2 (f), and VGF (g). The data are expressed as mean±SEM (n=3 per group). *P<.05, **P<.01, compared with Vehicle+NS shRNA treated group; #P<.05, ##P<.01, compared with Vehicle+NS shRNA treated group.